131 related articles for article (PubMed ID: 28950655)
21. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.
Ciccarese C; Iacovelli R; Brunelli M; Massari F; Bimbatti D; Fantinel E; De Marco V; Porcaro AB; Martignoni G; Artibani W; Tortora G
Eur J Cancer; 2017 Sep; 83():237-246. PubMed ID: 28756136
[TBL] [Abstract][Full Text] [Related]
22. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.
Levitzki A
Annu Rev Pharmacol Toxicol; 2013; 53():161-85. PubMed ID: 23043437
[TBL] [Abstract][Full Text] [Related]
23. Targeting Angiogenesis in Colorectal Cancer: Tyrosine Kinase Inhibitors.
Kircher SM; Nimeiri HS; Benson AB
Cancer J; 2016; 22(3):182-9. PubMed ID: 27341596
[TBL] [Abstract][Full Text] [Related]
24. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials.
Liu J; Sheng Z; Zhang Y; Li G
Target Oncol; 2016 Feb; 11(1):49-58. PubMed ID: 26206590
[TBL] [Abstract][Full Text] [Related]
25. Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer.
Grávalos C; Cassinello J; Fernández-Rañada I; Holgado E
Clin Colorectal Cancer; 2007 Nov; 6(10):691-9. PubMed ID: 18039422
[TBL] [Abstract][Full Text] [Related]
26. The Efficacy of Single-Agent Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Biologically Selected Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis of 19 Randomized Controlled Trials.
Li G; Gao S; Sheng Z; Li B
Chemotherapy; 2016; 61(4):179-89. PubMed ID: 26859739
[TBL] [Abstract][Full Text] [Related]
27. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
[TBL] [Abstract][Full Text] [Related]
28. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
29. EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation.
Koo DH; Kim KP; Choi CM; Lee DH; Lee JC; Lee JS; Jang SJ; Kim SW
Cancer Chemother Pharmacol; 2015 Jan; 75(1):197-206. PubMed ID: 25422153
[TBL] [Abstract][Full Text] [Related]
30. Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.
Burotto M; Ali SA; O'Sullivan Coyne G
Expert Opin Drug Saf; 2015 Jan; 14(1):97-110. PubMed ID: 25345687
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer.
Ni J; Zhang L
Chin Med J (Engl); 2016 Feb; 129(3):332-40. PubMed ID: 26831237
[TBL] [Abstract][Full Text] [Related]
32. The Future of Targeting FLT3 Activation in AML.
Leick MB; Levis MJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
[TBL] [Abstract][Full Text] [Related]
33. Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer.
Lee CC; Shiao HY; Wang WC; Hsieh HP
Expert Opin Investig Drugs; 2014 Oct; 23(10):1333-48. PubMed ID: 24921970
[TBL] [Abstract][Full Text] [Related]
34. Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases.
Luo S; Chen L; Chen X; Xie X
Oncotarget; 2015 Jun; 6(18):16725-34. PubMed ID: 26057469
[TBL] [Abstract][Full Text] [Related]
35. Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib.
Manson GV; Ma PC
Clin Lung Cancer; 2010 Jan; 11(1):57-60. PubMed ID: 20085869
[TBL] [Abstract][Full Text] [Related]
36. Cardiotoxicity induced by tyrosine kinase inhibitors.
Orphanos GS; Ioannidis GN; Ardavanis AG
Acta Oncol; 2009; 48(7):964-70. PubMed ID: 19734999
[TBL] [Abstract][Full Text] [Related]
37. Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.
Firwana B; Sonbol MB; Diab M; Raza S; Hasan R; Yousef I; Zarzour A; Garipalli A; Doll D; Murad MH; Al-Kali A
Int J Cancer; 2016 Mar; 138(6):1545-53. PubMed ID: 26455714
[TBL] [Abstract][Full Text] [Related]
38. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
[TBL] [Abstract][Full Text] [Related]
39. Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review.
Ranieri G; Pantaleo M; Piccinno M; Roncetti M; Mutinati M; Marech I; Patruno R; Rizzo A; Sciorsci RL
Crit Rev Oncol Hematol; 2013 Nov; 88(2):293-308. PubMed ID: 23768779
[TBL] [Abstract][Full Text] [Related]
40. Clinical uses and safety concerns of tyrosine kinase inhibitors with a focus on novel drugs: A narrative review.
Boskabadi SJ; Dashti A; Karevan S; Kargar-Soleimanabad S; Salehifar E
J Oncol Pharm Pract; 2023 May; ():10781552231174790. PubMed ID: 37170573
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
